On March 29, 2026, the final 2-year results from the APPLAUSE-IgAN trial were published in the New England Journal of Medicine. According to the NEJM publication, Fabhalta (iptacopan) slowed kidney function decline by 49.3% compared to placebo in patients with IgA nephropathy. The results were presented the same day as late-breaking data at the 2026 World Congress of Nephrology.
What makes this moment remarkable is context. Before December 2021, there were zero FDA-approved therapies specifically targeting IgAN. Patients were managed with blood pressure medications and general kidney-protective strategies. As of October 22, 2026, there are 7 FDA-approved treatments, 1 more under FDA review with a decision due November 30th according to its maker, others in late-stage trials, and an entirely new drug class entering the picture from an unexpected direction.
What the Fabhalta Data Actually Showed
Fabhalta is an oral complement factor B inhibitor that blocks the alternative complement pathway. In IgAN, this pathway amplifies the kidney damage caused by abnormal IgA1 deposits. Blocking that amplification is how Fabhalta is meant to reduce both the inflammation and the structural damage behind kidney function loss.
The APPLAUSE-IgAN trial enrolled adults with biopsy-confirmed IgAN and persistent proteinuria (protein in the urine, a marker of kidney damage) despite being on optimized supportive care. Patients were randomized 1:1 to Fabhalta or placebo and followed for 24 months. The primary endpoint was the annualized rate of kidney function decline, measured by estimated glomerular filtration rate (eGFR).
In the APPLAUSE-IgAN trial, patients on Fabhalta lost kidney function at a rate of 3.10mL/min/1.73m2 per year. The placebo group declined at 6.12mL/min/1.73m2 per year. That 49.3% difference was in line with the earlier interim analyses. The more striking finding, though, was the composite kidney failure endpoint: patients on Fabhalta had a 43% lower likelihood of a composite kidney failure event, which counted a sustained eGFR drop of 30% or more as well as kidney failure, dialysis, transplant or death from kidney failure (21.4% against 33.5%), with a hazard ratio of 0.57.
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage and loss of function over time.”
Vlado Perkovic, MD, University of New South Wales, APPLAUSE-IgAN Steering Committee Co-Chair
On proteinuria, according to the APPLAUSE-IgAN trial data, 40.7% of Fabhalta patients achieved a 24-hour urine protein-to-creatinine ratio below 1g/g, compared to 23.7% on placebo. Overall adverse event rates were similar to placebo, 87.0% against 89.1%, but serious infections were more common on Fabhalta, at 6.7% against 2.1%, and no one died. Fabhalta carries a boxed warning for serious infections from encapsulated bacteria, so vaccination comes before the first dose.
Fabhalta first received accelerated FDA approval in August 2024 for reducing proteinuria in IgAN. Novartis submitted the 2-year APPLAUSE data for traditional (full) approval under priority review, and the FDA granted it on July 16, 2026. Novartis describes Fabhalta as the first and only complement inhibitor shown to significantly slow kidney function decline in IgAN.
How IgAN Went From Zero to 7 Approved Treatments
The approvals came in quick succession, 7 in under 5 years.
According to FDA records, in December 2021, TARPEYO (budesonide delayed-release) became the first FDA-approved therapy for IgAN, receiving accelerated approval based on proteinuria reduction. It was followed by Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist, which received accelerated approval in February 2023 and full approval in September 2024 after confirmatory data from the PROTECT trial showed it significantly slowed kidney function decline over 2 years.
Then things moved fast. The FDA granted Fabhalta (iptacopan) accelerated approval in August 2024 as the first complement inhibitor for IgAN. Vanrafia (atrasentan) followed in April 2025 as a selective endothelin A receptor antagonist. The FDA then approved Voyxact (sibeprenlimab), an APRIL inhibitor, in November 2025 after the VISIONARY trial showed a 51% reduction in proteinuria compared with placebo at 9 months. After this article was first published, the FDA approved a sixth, Trutakna (atacicept), which blocks both BAFF and APRIL, on July 7, 2026. A seventh followed on October 21, 2026, when AstraZeneca announced accelerated approval of Ultomiris (ravulizumab) to reduce proteinuria in adults at risk of progression. AstraZeneca says it has not been established whether Ultomiris slows kidney function decline, which its I CAN trial measures at week 106.
These drugs work through 4 different biological pathways. TARPEYO reduces gut-associated immune activity. Filspari targets endothelin and angiotensin pathways. Fabhalta blocks complement factor B. Vanrafia selectively blocks endothelin A receptors. Voyxact inhibits APRIL, a protein that drives the production of the abnormal IgA1 antibodies at the root of the disease, and Trutakna blocks both APRIL and BAFF. Ultomiris blocks complement C5, a later step in the same immune system Fabhalta targets. For patients and nephrologists, this means real choices based on individual disease characteristics, tolerability, and treatment goals.
Latest for IgA Nephropathy
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Trial of HRS-5965 Capsule in Primary IgA Nephropathy (Phase 3, Chengdu Suncadia Medicine Co.)ClinicalTrials.gov
- Help payingThe Assistance Fund reopened its Immunoglobulin A Nephropathy (IgAN) fundTrial Friend
Free email alert
Want the next IgA Nephropathy update without checking back?
We email you when a new IgA Nephropathy trial opens or an FDA decision comes out.
You'll get trial alerts and disease updates for IgA Nephropathy, and you can turn either off anytime. We never share your email. Privacy policy
Biohaven Enters IgAN With a Different Approach
The approved therapies work on inflammation, kidney damage or, with Voyxact and Trutakna, how much abnormal IgA1 the body makes. None of them pulls the antibodies already in the blood out of circulation. That is where Biohaven's BHV-1400 program gets interesting.
BHV-1400 is a TRAP (Targeted Removal of Aberrant Protein) degrader. It is a bispecific molecule that binds specifically to galactose-deficient IgA1 (Gd-IgA1), the abnormal form of IgA1 that causes IgAN, and directs it to the liver for degradation. The key distinction, according to Biohaven, is that it selectively removes the disease-causing protein while leaving normal IgA, IgG, and IgM antibodies intact. In theory, this goes after the root cause rather than managing downstream consequences.
The early data comes from small studies and individual patients. In Biohaven's Phase 1 study in healthy volunteers, a single 500mg injection under the skin lowered Gd-IgA1 by up to 81%, with reductions beginning within hours. In people with IgAN, Biohaven reported on May 27, 2026 that Gd-IgA1 fell by more than 60% on average within 48 hours and by about 70% within the first month of dosing. Biohaven presented 2 patient cases at the 44th J.P. Morgan Healthcare Conference in January 2026 and reported clinical improvements in both: a young woman with early-stage disease experienced complete resolution of chronic blood in her urine (hematuria) within weeks, and a man with moderate-to-severe kidney function loss saw a 60%+ reduction in proteinuria and a 24% improvement in eGFR within weeks of dosing.
According to Biohaven's statements, the company completed a Q4 2025 meeting with the FDA to align on pivotal study design and planned to start that study in 2026 using proteinuria reduction (UPCR) as a surrogate endpoint for accelerated approval. ClinicalTrials.gov listed the Phase 3 study (NCT07642050) as not yet recruiting when checked on November 5, 2026, and Biohaven said on October 29, 2026 that it is on track to start the study in the fourth quarter of 2026. Biohaven reported no drug-related adverse events in the Phase 1b expansion cohort as of January 2026.
After the FDA's Complete Response Letter for troriluzole in spinocerebellar ataxia in November 2025, Biohaven announced plans to cut its annual direct R&D spending by about 60% and paused or deferred programs it did not consider a priority. BioSpace reported in November 2025 that the programs Biohaven kept included BHV-1400 in IgAN, BHV-1300 in Graves' disease, opakalim and taldefgrobep alfa. IgAN has a defined regulatory route, and Biohaven plans to seek accelerated approval on proteinuria reduction, the same surrogate endpoint several of the approved IgAN drugs used.
What This Means for IgAN Patients
The practical reality for someone diagnosed with IgAN today is completely different from what it was 4 years ago. If you are wondering how many IgA nephropathy treatments are available now, the answer, as of October 2026, is 7 approved therapies targeting different parts of the disease pathway, a growing pipeline of investigational options, and an emerging drug class that aims to remove the abnormal antibody directly.
Having options also creates complexity. Choosing a new IgAN medication depends on your level of proteinuria, how fast your eGFR is falling, your other health conditions, and practical demands such as the vaccinations required before starting Fabhalta. Some patients may benefit from combination approaches that target multiple mechanisms at once. These are conversations to have with a nephrologist who understands the latest data.
For patients considering IgAN clinical trials, medication rules matter too. Several of these trials exclude patients currently on other IgAN-targeted therapies, require specific washout periods, or have proteinuria thresholds that may be harder to meet if you are already on treatment. A common question is: will my medication affect clinical trial eligibility? Trial Friend's medication conflict checker can help you see how each drug interacts with specific trial criteria.
Patients weighing a trial against these drugs can use the lab numbers check to see which recruiting IgA nephropathy trials list cutoffs their latest results fall within.
Before December 2021, the standard advice for IgAN patients was to optimize blood pressure control, monitor proteinuria, and hope for the best. That advice is not wrong today, but it is no longer the whole story. The treatment options are real, the pipeline is deep, and the science is moving fast. For a disease that once had nothing, that is a real shift.
